FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
 - EconoTimes)
- The members of the Advisory Committee voted 12-2 for an approval of iGlarLixi
- Both lixisenatide and iGlarLixi for the treatment of type 2 diabetes were discussed at the Advisory Committee meeting. The FDA had not requested a vote on lixisenatide
- FDA regulatory decisions on lixisenatide and iGlarLixi are expected in July and August 2016, respectively
- Zealand reiterates its financial guidance for 2016, including expectations of increasing royalty revenue and additional milestone revenue of DKK 200 million / EUR 27 million
COPENHAGEN, Denmark, May 25, 2016 -- Zealand announced today that the Endocrinologic and Metabolic Drugs Advisory Committee of the US Food and Drug Administration (FDA) has discussed lixisenatide and iGlarLixi for the treatment of adults with type 2 diabetes. Following the discussions, the Advisory Committee members voted 12 to 2 (with 1 non-vote) to recommend approval of the New Drug Application (NDA) for iGlarLixi in the US. The Advisory Committee was not asked by the FDA to vote on the approval of the NDA for lixisenatide.
Lixisenatide is a once-daily prandial GLP-1 receptor agonist, invented by Zealand with global development and commercial rights licensed to Sanofi. IGlarLixi is a fixed-ratio combination of lixisenatide and basal insulin glargine 100 Units/mL (marketed as Lantus(r)), developed by Sanofi under the license agreement with Zealand. The NDAs for both products are undergoing regulatory review and a decision by the FDA is expected for lixisenatide in July 2016 and for iGlarLixi in August 2016.
In a comment, Britt Meelby Jensen, Chief Executive Officer of Zealand, said: "I am very pleased that the FDA Advisory Committee so clearly has recommended an approval of iGlarLixi in the US as a new treatment for adults with type 2 diabetes. This positive outcome, and the supportive conclusion on lixisenatide as a stand-alone therapy, have taken us an important step closer to potentially having two medicines based on a Zealand invention being available on the US market later this year."
She continued: "The prospect of growing royalty revenue from lixisenatide and iGlarLixi is an important element in the execution of our strategy of building a portfolio of proprietary Zealand products to support accelerated value creation. Our portfolio includes ZP1848, a novel GLP-2 analog, which is in Phase II development for short bowel syndrome, and ZP4207, a glucagon in Phase II as a single-dose version for severe hypoglycemia in diabetes and in preparation for Phase II as a multiple-dose version for use in a dual-hormone artificial pancreas device. All programs are advancing as planned and we look forward to updating the market on further news in the coming months."
